Why Farbe Firma is the Top Manufacturer of Neostigmine Methylsulfate Injection
- Maulik Sudani
- 1 day ago
- 6 min read
Last Updated: May 28, 2026
TL;DR: Neostigmine Methylsulfate Injection — a sterile parenteral solution of the quaternary-ammonium reversible cholinesterase inhibitor neostigmine methylsulfate, supplied most commonly as 0.5 mg/mL and 2.5 mg/mL strengths in 1 mL ampoules — is the global standard for pharmacological reversal of non-depolarising neuromuscular blockade at the end of surgery, for symptomatic treatment of myasthenia gravis, and for the management of postoperative urinary retention and paralytic ileus. By blocking acetylcholinesterase at the neuromuscular junction it raises synaptic acetylcholine and restores muscle strength within minutes. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Neostigmine Methylsulfate Injection at our Gujarat, India facility and supplies it to operating-theatre tenders, hospital pharmacies, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Quaternary-ammonium reversible acetylcholinesterase inhibitor / cholinergic — Neostigmine Methylsulfate Injection is the WHO Essential Medicine for reversal of rocuronium-, vecuronium- and atracurium-induced neuromuscular blockade at the end of anaesthesia, the parenteral first-line treatment of myasthenic crisis and the standard intervention for postoperative urinary retention and adynamic paralytic ileus. Because it does not cross the blood-brain barrier, peripheral cholinergic activity is achieved without central effects.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, qualified clear-glass ampoule and vial filling lines, dedicated handling for a highly potent, photosensitive cholinergic API, validated terminal-sterilisation cycles and full container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, drug master files and CEP-style documentation for registrations across regulated and emerging markets — including ministry-of-health anaesthesia and operating-theatre tenders.
End-to-end CDMO services: Contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tender-ready ampoule and vial packaging and logistics coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Neostigmine Methylsulfate Injection Demands a Premium Manufacturer
Neostigmine Methylsulfate Injection is the quiet workhorse at the end of almost every general-anaesthetic case in the world. When the surgeon closes and the anaesthetist needs to return spontaneous breathing and protective airway reflexes to a patient still partly paralysed by a non-depolarising neuromuscular blocker, neostigmine — usually co-administered with glycopyrrolate or atropine to control its muscarinic side effects — is the agent that reverses the block within minutes. The same molecule is used to manage myasthenic patients in crisis, to restart a postoperative bowel that has gone silent, and to overcome non-obstructive urinary retention after surgery. In each of those clinical situations the drug is given to a vulnerable, often unstable patient, and the difference between a clean reversal and a respiratory complication can come down to the potency and sterility of a single 1 mL ampoule.
That clinical reality places real demands on the manufacturer. Neostigmine methylsulfate is a highly water-soluble quaternary-ammonium salt of low concentration (0.5 mg/mL and 2.5 mg/mL are the dominant strengths) and small fill volume, which means assay precision, fill-volume control and visible-particulate inspection have to be excellent for a product that will be drawn up under operating-room time pressure. The molecule is sensitive to pH, light and oxidation; it must be packed in pH-stabilised solutions, protected from light through its shelf life, and validated against ICH Q1A and Q1B stability protocols. Choosing a Neostigmine Methylsulfate Injection manufacturer that treats potency control, particulate inspection and operating-room-grade labelling as core engineering disciplines is what keeps anaesthesia teams safe at the moment of reversal.
What Sets a World-Class Neostigmine Methylsulfate Injection Manufacturer Apart
A world-class manufacturer of Neostigmine Methylsulfate Injection invests in three areas that weaker suppliers underfund: precision assay control of a low-strength potent API, particulate and sterility excellence in a small-volume parenteral that will be injected intravenously and rapidly, and unambiguous strength differentiation between the 0.5 mg/mL and 2.5 mg/mL ampoules that share the same theatre tray. It starts with the active pharmaceutical ingredient — pharmacopoeial-grade neostigmine methylsulfate sourced from qualified, audited API manufacturers, with full impurity profiling, related-substances control and certificates of analysis cross-checked by the receiving laboratory before any material enters production.
Formulation, filling and packaging then have to protect the molecule end to end. The solution is built to a controlled pH, with stability-supporting excipients, and filled under ISO Class 5 air into clear or amber glass ampoules and small vials, with light-protective secondary packaging where required. In-process assay confirms label strength, container-closure integrity is verified, and stability is tracked under ICH Q1A long-term and accelerated conditions as well as ICH Q1B photostability protocols. Critically, the artwork programme keeps the 0.5 mg/mL and 2.5 mg/mL strengths visually distinct — different ampoule colours, different carton colours, large strength callouts — because both strengths sit side-by-side on the anaesthesia trolley and selection errors are not acceptable.
Quality Systems Behind Every Neostigmine Methylsulfate Injection
Every Farbe Firma Neostigmine Methylsulfate Injection batch is released only after a full stack of quality checks: HPLC assay against USP, BP, IP or EP reference standards, related-substances and degradation-product profiling, pH, osmolarity, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, container-closure integrity, and fill-volume verification for both the 0.5 mg/mL and 2.5 mg/mL ampoule formats. Certificates of analysis are issued with full traceability back to API lot, primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, calibrated sterilisation and depyrogenation equipment, validated terminal sterilisation cycles with load mapping for each container format, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Stability is tracked under both long-term (30 °C / 65 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions — Zone IVb included — and the product is challenged against ICH Q1B photostability requirements so we can assure customers that the Neostigmine Methylsulfate Injection they buy today will still meet specification when it reaches the operating theatre months later in any climate.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Neostigmine Methylsulfate Injection Manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables across anaesthesia, critical-care, anti-infective, obstetric, neonatal and supportive-care categories. For Neostigmine Methylsulfate Injection specifically, we supply 0.5 mg/mL and 2.5 mg/mL strengths in 1 mL clear-glass ampoules under WHO-GMP conditions, with country-specific strengths, container formats and pack configurations available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier ready to hand for registration in the buyer's target market.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination. When a buyer needs Neostigmine Methylsulfate Injection at tender scale — and operating-theatre and anaesthesia procurements are almost always high-volume, multi-strength and label-sensitive — our regulatory, manufacturing and logistics teams move as one: dossier, artwork, production slot and shipment plan delivered as a single coordinated package, with a single accountable point of contact.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing, pH stabilisation, particulate control, sterilisation, container-closure and stability choices in real detail. For a drug given at the most fragile minute of the anaesthetic case, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Neostigmine Methylsulfate Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Neostigmine Methylsulfate Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, qualified ampoule and vial filling lines, qualified water-for-injection systems, validated terminal sterilisation cycles and continuous environmental monitoring. WHO-GMP, USP, BP, IP and EP compliance documentation is available on request.
Which strengths and pack sizes of Neostigmine Methylsulfate Injection do you supply?
Our standard presentations are 0.5 mg/mL and 2.5 mg/mL neostigmine methylsulfate solution in 1 mL clear-glass ampoules. Custom fill volumes, vial presentations, country-specific pack configurations and combination presentations with glycopyrrolate are available under contract manufacturing agreements — share your specification and our technical team will quote within 48 hours.
Can Farbe Firma support country-specific registrations for Neostigmine Methylsulfate Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. Our regulatory team has supported registrations across 30+ countries in Africa, LATAM, CIS, GCC, MENA and Southeast Asia, including anaesthesia and operating-theatre tender programmes for ministry-of-health buyers.
How does Farbe Firma assure the potency and stability of Neostigmine Methylsulfate Injection?
We control pH within a validated specification, run HPLC assay and related-substances testing on every batch, package in pharmacopoeial glass with light-protective secondary cartons where required, and qualify each batch against ICH Q1A long-term and accelerated stability protocols plus ICH Q1B photostability. Endotoxin, sterility and container-closure integrity are confirmed on every batch, and the 0.5 mg/mL and 2.5 mg/mL strengths are kept visually distinct in artwork to prevent selection error on the anaesthesia trolley.
What is the minimum order quantity for Neostigmine Methylsulfate Injection contract manufacturing?
MOQs vary by strength, container format, label complexity and dossier requirements. For both 0.5 mg/mL and 2.5 mg/mL presentations we accommodate hospital-scale and full-tender-scale orders. Contact director@farbefirma.org for a specific quotation against your specification.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments